VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

Historical Holders from Q1 2023 to Q3 2025

Symbol
VYNE on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
18,514,484
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
3,924,005
Holdings value
$1,315,944
% of all portfolios
0%
Number of holders
31
Number of buys
14
Number of sells
-26
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CITADEL ADVISORS LLC 0% -1% $1,250 -$367,360 3,732 -99.7% Kenneth Griffin 30 Sep 2025

Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 3,924,005 $1,315,944 -$9,032,746 $0.335 31
2025 Q2 8,048,768 $13,279,291 +$1,503,898 $1.65 44
2025 Q1 7,109,939 $11,401,092 -$2,382,241 $1.58 36
2024 Q4 7,028,274 $23,320,995 +$606,162 $3.35 34
2024 Q3 7,312,555 $14,256,902 -$1,226,342 $1.88 31
2024 Q2 7,942,286 $16,030,293 +$243,077 $1.97 30
2024 Q1 6,405,086 $19,663,149 +$378,435 $3.07 29
2023 Q4 7,863,834 $18,322,345 +$17,207,859 $2.33 32
2023 Q3 360,099 $1,445,870 -$33,734 $4.04 20
2023 Q2 375,960 $1,532,386 +$198,131 $4.1 19
2023 Q1 335,259 $1,031,948 +$1,031,948 $3.08 19